Atlas Trials

Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study

Clinical trial NCT05685550 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05685550
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Progression Free Survival(PFS)
Start date
2023-04-12
Primary completion
2025-12-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.